The Limited Times

Now you can see non-English news...

Corona vaccine: According to the study, Novavax is highly effective

2021-06-16T17:22:16.136Z


According to the manufacturer, the protein vaccine from Novavax has proven itself in studies, and approval is to be applied for in the third quarter. The company aims to produce at least 100 million cans per month.


Enlarge image

Vaccination with Novavax as part of a study

Photo: Alastair Grant / dpa

The pharmaceutical company Novavax reports that its corona vaccine has proven itself in clinical studies.

According to the US company's announcement, the vaccination provided 100 percent protection against moderate to severe Covid-19 diseases.

Almost 30,000 adults in the United States and Mexico took part in the study, two thirds received the vaccine and one third a placebo.

A total of 77 people fell ill with Covid-19 during the study period, only 14 of them in the group of those who were vaccinated.

The vaccination was therefore more than 90 percent effective.

The vaccinated suffered only a mild illness, while of the 63 cases in the placebo group, ten were moderately and seven were seriously ill.

Effective against the alpha variant

According to the communication, the vaccine was generally well tolerated.

The most common complaints after vaccination were pain at the injection site, fatigue, and headache and body aches that lasted less than two days.

While the study was running, the alpha variant (B.1.1.7) became the most common corona variant in the two countries.

The vaccine obviously protects against this mutant as well.

This was already indicated by a study that was carried out in Great Britain.

In a study in South Africa, on the other hand, there was a reduced effectiveness against the beta mutant there: against this variant, the effectiveness fell to just under 49 percent.

Novavax announced that it would apply for approval in the third quarter - between July and September.

The manufacturer had actually wanted to be on the market faster, but announced in May that it was not aiming for approval in the USA, the EU and Great Britain until after July.

According to its own information, the company can initially produce 100 million vaccine doses per month and then increase this to 150 million.

The preparation is a protein vaccine, so virus proteins are given directly into the body so that the body sharpens its defenses against them.

Novavax thus differs from the agents previously approved in the EU, which are either RNA vaccines (Biontech / Pfizer and Moderna) or contain a virus vector (AstraZeneca and Johnson & Johnson).

Novavax is currently also testing its vaccine in children and adolescents aged 12 to 18 years.

wbr

Source: spiegel

All tech articles on 2021-06-16

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.